After building momentum for weeks, congressional action on patent reform legislation is beginning to slow. The Senate Judiciary Committee has twice postponed markup of the bi-partisan PATENT Act in recent weeks. Reportedly, one reason behind the pause is a push by the pharmaceutical industry to include amendments that would limit the Patent and Trademark Office’s (PTO) authority to reevaluate the validity of issued patents at the request of third-parties that haven’t themselves been accused of infringement.
top of page
Recent Posts
See AllOn November 21, 2024, the Senate Judiciary Committee, by a vote of 11-10, voted to advance S. 2220, the Promoting and Respecting...
On September 17, 2024, United for Patent Reform joined the nation’s leading microchip and technology manufacturers, generic and...
On September 17, 2024, United For Patent Reform joined a host of organizations representing the nation's leading technology and microchip...
bottom of page